[1]邓永,唐腾骞,张雷达.miRNA-200b逆转肝细胞癌HepG2细胞对索拉菲尼的耐药性及其相关机制[J].陆军军医大学学报(原第三军医大学学报),2021,43(22):2435-2440.
 DENG Yong,TANG Tengqian,ZHANG Leida.MiRNA-200b reverses drug resistance of hepatocellular carcinoma HepG2 cells to sorafenib and its underlying mechanism [J].J Amry Med Univ (J Third Mil Med Univ),2021,43(22):2435-2440.
点击复制

miRNA-200b逆转肝细胞癌HepG2细胞对索拉菲尼的耐药性及其相关机制(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
43卷
期数:
2021年第22期
页码:
2435-2440
栏目:
基础医学
出版日期:
2021-11-30

文章信息/Info

Title:
MiRNA-200b reverses drug resistance of hepatocellular carcinoma HepG2 cells to sorafenib and its underlying mechanism
 
作者:
邓永唐腾骞张雷达
陆军军医大学(第三军医大学)第一附属医院肝胆外科
Author(s):
DENG Yong TANG Tengqian ZHANG Leida

Department of Hepatobiliary Surgery, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China

关键词:
肝细胞癌miRNA-200b索拉菲尼耐药
Keywords:
 
分类号:
R735.7; R915; R979.1
文献标志码:
A
摘要:
目的探究miRNA-200b对肝细胞癌索拉菲尼耐药的影响,以期延缓或改善晚期肝癌患者对索拉菲尼的耐药,增加索拉菲尼的疗效。方法通过逐步提高培养基中索拉菲尼浓度的方法建立索拉菲尼耐药的肝细胞癌HepG2-SR细胞系,并通过实时荧光定量(RT-PCR)法检测HepG2-SR细胞系和其母本HepG2细胞系中miRNA-200b的表达差异, 同时检测HepG2-SR细胞转染miRNA-200b mimics后miRNA-200b表达的变化;CCK-8法检测转染后HepG2-SR细胞对索拉菲尼敏感度的改变;划痕实验和transwell实验检测转染前后HepG2-SR细胞迁移和侵袭能力的改变;流式细胞仪检测转染前后HepG2-SR细胞凋亡情况;Western-blot检测转染前后上皮间质转变(epithelial mesenchymal transition, EMT)标志物的改变。结果耐药株HepG2-SR细胞对索拉菲尼的耐药性显著高于其母本株HepG2,miRNA-200b的表达显著低于其母本株HepG2;HepG2-SR细胞转染miRNA-200b mimics后miRNA-200b表达显著升高,索拉菲尼半抑制浓度(IC50)显著降低,细胞迁移率显著降低,细胞侵袭能力显著降低,细胞凋亡显著增加,上皮细胞标志E-Cadherin表达增加,间质细胞标志N-Cadherin、Vimentin表达减弱。结论miRNA-200b抑制HepG2-SR细胞的增殖、迁移、侵袭和EMT,促进细胞凋亡,从而逆转索拉菲尼耐药性。
 
Abstract:
ObjectiveTo explore the effect of miRNA-200b on sorafenib resistance in hepatocellular carcinoma cells in order to increase the efficacy of the drug in advanced liver cancer patients. MethodsSorafenib resistant hepatocellular carcinoma HepG2-SR cell line was established by gradually increasing the concentration of sorafenib in the culture medium. The expression of miRNA-200b in HepG2-SR cells, HepG2 cells and miRNA-200b transfected HepG2-SR cells was detected by real-time fluorescence quantitative assay (RT-PCR). In HepG2-SR cells before and after transfection, sorafenib sensitivity was detected by CCK-8 assay, migration and invasion abilities were detected by wound-healing assay and Transwell assay, cell apoptosis was measured by flow cytometry, and expression levels of epithelial mesenchymal transition (EMT) markers were studied by Western blotting. ResultsSorafenib resistance was significantly higher and expression of miRNA-200b was significantly lower in HepG2-SR cells than HepG2 cells. Transfection of miRNA-200b mimics resulted in significantly increased miRNA-200b expression, decreased IC50 of sorafenib, reduced cell migration rate and cell invasion, enhanced apoptosis and increased expression of E-cadherin but decreased expression of N-cadherin and Vimentin. ConclusionMiRNA-200b reversed sorafenib resistance of HepG2-SR cells by inducing apoptosis and inhibiting cell proliferation, migration, invasion and EMT.
 

参考文献/References:

[1]BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
 
[2]BALOGH J, VICTOR D, ASHAM E H, et al. Hepatocellular carcinoma: a review[J]. J Hepatocell Carcinoma, 2016, 3: 41-53. DOI: 10.2147/jhc.s61146.
 
[3]FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. DOI: 10.1016/s0140-6736(18)30010-2.
 
[4]CHENG A L, KANG Y K, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34. DOI: 10.1016/s1470-2045(08)70285-7.
 
[5]BRUIX J, RAOUL J L, SHERMAN M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial[J]. J Hepatol, 2012, 57(4): 821-829. DOI: 10.1016/j.jhep.2012.06.014.
 
[6]BERASAIN C. Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?[J]. Gut, 2013, 62(12): 1674-1675. DOI: 10.1136/gutjnl-2013-304564.
 
[7]LU T X, ROTHENBERG M E. MicroRNA[J]. J Allergy Clin Immunol, 2018, 141(4): 1202-1207. DOI: 10.1016/j.jaci.2017.08.034.
 
[8]SI W, SHEN J, ZHENG H, et al. The role and mechanisms of action of microRNAs in cancer drug resistance[J]. Clin Epigenetics, 2019, 11(1): 25. DOI: 10.1186/s13148-018-0587-8.
 
[9]GOLLAVILLI P N, PARMA B, SIDDIQUI A, et al. The role of miRNA-200b/c in balancing EMT and proliferation revealed by an activity reporter[J]. Oncogene, 2021, 40(12): 2309-2322. DOI: 10.1038/s41388-021-01708-6.
 
[10]PIPERIGKOU Z, FRANCHI M, RIETHMLLER C, et al. MiRNA-200b restrains EMT and aggressiveness and regulates matrix composition depending on ER status and signaling in mammary cancer[J]. Matrix Biol Plus, 2020, 6/7: 100024. DOI: 10.1016/j.mbplus.2020.100024.
 
[11]FENG B, WANG R, CHEN L B. Review of miRNA-200b and cancer chemosensitivity[J]. Biomed Pharmacother, 2012, 66(6): 397-402. DOI: 10.1016/j.biopha.2012.06.002.
 
[12]POGRIBNY I P, FILKOWSKI J N, TRYNDYAK V P, et al. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin[J]. Int J Cancer, 2010, 127(8): 1785-1794. DOI: 10.1002/ijc.25191.
 
[13]LIU J, ZHANG X, HUANG Y, et al. MiRNA-200b and miRNA-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases[J]. Oncol Lett, 2019, 17(2): 1453-1460. DOI: 10.3892/ol.2018.9745.
 
[14]LV Z, WEI J L, YOU W X, et al. Disruption of the c-Myc/miRNA-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer[J]. J Transl Med, 2017, 15(1): 257. DOI: 10.1186/s12967-017-1357-7.
 
[15]HAIDER T, PANDEY V, BANJARE N, et al. Drug resistance in cancer: mechanisms and tackling strategies[J]. Pharmacol Rep, 2020, 72(5): 1125-1151. DOI: 10.1007/s43440-020-00138-7.
 
[16]GIOVANNETTI E, EROZENCI A, SMIT J, et al. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice[J]. Crit Rev Oncol Hematol, 2012, 81(2): 103-122. DOI: 10.1016/j.critrevonc.2011.03.010.
 
[17]CHEN L, WANG X, ZHU Y, et al. miR-200b-3p inhibits proliferation and induces apoptosis in colorectal cancer by targeting Wnt1[J]. Mol Med Rep, 2018, 18(3): 2571-2580. DOI: 10.3892/mmr.2018.9287.
 
[18]WANG B G, LI J S, LIU Y F, et al. MicroRNA-200b suppresses the invasion and migration of hepatocellular carcinoma by downregulating RhoA and circRNA_000839[J]. Tumour Biol, 2017, 39(7): 1010428317719577. DOI: 10.1177/1010428317719577.
 
[19]THIERY J P, ACLOQUE H, HUANG R Y, et al. Epithelial-mesenchymal transitions in development and disease[J]. Cell, 2009, 139(5): 871-890. DOI: 10.1016/j.cell.2009.11.007.
 
[20]HUNG C S, LIU H H, LIU J J, et al. MicroRNA-200a and -200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers[J]. Ann Surg Oncol, 2013, 20(3): 360-368. DOI: 10.1245/s10434-012-2482-4.
 
[21]TSAI S C, LIN C C, SHIH T C, et al. The miRNA-200b-ZEB1 circuit regulates diverse stemness of human hepatocellular carcinoma[J]. Mol Carcinog, 2017, 56(9): 2035-2047. DOI: 10.1002/mc.22657.
 

相似文献/References:

[1]郭靖,尚杨杨,汪荣泉.结直肠癌及缺氧的结直肠癌细胞中HIF-1α与miRNA-200b表达的相关性[J].陆军军医大学学报(原第三军医大学学报),2016,38(06):545.
 Guo Jing,Shang Yangyang,Wang Rongquan.Correlation of HIF-1α and miRNA-200b expression in human colorectal cancer tissues and hypoxia-induced colorectal cancer cells[J].J Amry Med Univ (J Third Mil Med Univ),2016,38(22):545.

更新日期/Last Update: 2021-11-23